Results from expanded access programs: a review of academic literature 159 7♦ Comparison with other data When comparing the expanded access program with pre-clinical trials, the authors conclude that: The potential of TL-118 in combination with standard chemotherapy in the suppression of tumor growth was also demonstrated in a pre-clinical trial in an orthotropic pancreatic cancer model in mice (unpublished data), mice with metastatic colorectal cancer and a phase II study in metastatic prostate cancer. Moreover, a phase II clinical trial of TL-118 for pancreatic cancer patients that have not yet been treated with chemotherapy was initiated by the sponsor, Tiltan Pharma Ltd. According to ClinicalTrials.gov (NCT01509911), this trial was initiated in 2012 and is still ongoing. No updates have been posted since February 5, 2016. Conclusion The authors conclude that: ‘This report describes a new approach in treating pancreatic cancer, enabling patients to obtain a longer progression-free survival using this new anti-angiogenic drug combination, added on standard chemotherapy.’
RkJQdWJsaXNoZXIy MTk4NDMw